Jazz Pharmaceuticals Plc (JAZZ) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1125021,
    "name": "Jazz Pharmaceuticals Plc",
    "stock_name": "Jazz Pharmaceuticals Plc",
    "full_name": "Jazz Pharmaceuticals Plc",
    "name_url": "stocks-analysis/jazz-pharmaceuticals-plc",
    "exchange": 210,
    "exchangecode": "NAS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "166.91",
    "chg": 0.2,
    "chgp": "0.12%",
    "dir": 1,
    "prev_price": "166.71",
    "mcapval": "7,876.55",
    "mcap": "Small Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 2305,
    "indexname": "S&P 500",
    "isin": "IE00B4Q5ZN47",
    "curr_date": "Dec 04",
    "curr_time": "",
    "bse_nse_vol": "1.69 M",
    "exc_status": "Active",
    "traded_date": "Dec 04, 2025",
    "traded_date_str": "2025 12 04",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/jazz-pharmaceuticals-plc-1125021-210&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Is Jazz Pharmaceuticals Plc technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-jazz-pharmaceuticals-plc-technically-bullish-or-bearish-3547402",
        "imagepath": "",
        "date": "2025-09-20 19:54:33",
        "description": "As of 18 August 2025, the technical trend for Jazz Pharmaceuticals Plc has changed from sideways to mildly bullish. Key indicators supporting this stance include a bullish MACD on both the weekly and monthly time frames, bullish Bollinger Bands, and a bullish daily moving average. However, the Dow Theory presents a mixed view with a mildly bearish weekly signal and a mildly bullish monthly signal. The stock has outperformed the S&P 500 over the past week and month, returning 2.13% and 11.49% respectively, while it has lagged behind in the year-to-date and longer-term periods. Overall, the current technical stance is mildly bullish, driven by positive momentum in several indicators despite some mixed signals...."
      },
      {
        "title": "Is Jazz Pharmaceuticals Plc overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-jazz-pharmaceuticals-plc-overvalued-or-undervalued-3543790",
        "imagepath": "",
        "date": "2025-09-20 18:28:45",
        "description": "As of 5 August 2025, Jazz Pharmaceuticals Plc has moved from an attractive to a risky valuation grade. The company appears to be overvalued, as indicated by its P/E ratio of 14, which is lower than the peer average of approximately 16.11, and a PEG ratio of 0.68, suggesting potential growth at a reasonable price compared to its peers. Additionally, the EV to EBITDA ratio stands at 7.69, which is more favorable than some peers like Neurocrine Biosciences, Inc. with an EV to EBITDA of 25.28, but still reflects a concern given the overall risk profile.\n\nIn terms of peer comparison, Jazz Pharmaceuticals is positioned against companies like Viatris, Inc., which has a P/E ratio of 44.86, and Neurocrine Biosciences, Inc., which has a significantly higher P/E of 37.08. While Jazz has shown a 1-year stock return of 19.74%, outperforming the S&P 500's 17.14%, its longer-term performance has been underwhelming, with a..."
      },
      {
        "title": "Jazz Pharmaceuticals Forms Golden Cross, Signaling Potential Bullish Breakout",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/jazz-pharmaceuticals-forms-golden-cross-signaling-potential-bullish-breakout-3537566",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/9/JazzPharmaceuti_goldencross_3537566.png",
        "date": "2025-09-19 16:03:49",
        "description": "Jazz Pharmaceuticals Plc has recently achieved a Golden Cross, indicating a potential shift in market sentiment. The stock has shown positive trends in its moving averages and MACD, outperforming the S&P 500. Despite past challenges, recent indicators suggest a possible upward momentum in its performance."
      }
    ],
    "total": 8,
    "sid": "1125021",
    "stock_news_url": "https://www.marketsmojo.com/news/jazz-pharmaceuticals-plc-1125021"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

Is Jazz Pharmaceuticals Plc technically bullish or bearish?

2025-09-20 19:54:33

As of 18 August 2025, the technical trend for Jazz Pharmaceuticals Plc has changed from sideways to mildly bullish. Key indicators supporting this stance include a bullish MACD on both the weekly and monthly time frames, bullish Bollinger Bands, and a bullish daily moving average. However, the Dow Theory presents a mixed view with a mildly bearish weekly signal and a mildly bullish monthly signal. The stock has outperformed the S&P 500 over the past week and month, returning 2.13% and 11.49% respectively, while it has lagged behind in the year-to-date and longer-term periods. Overall, the current technical stance is mildly bullish, driven by positive momentum in several indicators despite some mixed signals....

Is Jazz Pharmaceuticals Plc overvalued or undervalued?

2025-09-20 18:28:45

As of 5 August 2025, Jazz Pharmaceuticals Plc has moved from an attractive to a risky valuation grade. The company appears to be overvalued, as indicated by its P/E ratio of 14, which is lower than the peer average of approximately 16.11, and a PEG ratio of 0.68, suggesting potential growth at a reasonable price compared to its peers. Additionally, the EV to EBITDA ratio stands at 7.69, which is more favorable than some peers like Neurocrine Biosciences, Inc. with an EV to EBITDA of 25.28, but still reflects a concern given the overall risk profile. In terms of peer comparison, Jazz Pharmaceuticals is positioned against companies like Viatris, Inc., which has a P/E ratio of 44.86, and Neurocrine Biosciences, Inc., which has a significantly higher P/E of 37.08. While Jazz has shown a 1-year stock return of 19.74%, outperforming the S&P 500's 17.14%, its longer-term performance has been underwhelming, with a...

Jazz Pharmaceuticals Forms Golden Cross, Signaling Potential Bullish Breakout

2025-09-19 16:03:49

Jazz Pharmaceuticals Plc has recently achieved a Golden Cross, indicating a potential shift in market sentiment. The stock has shown positive trends in its moving averages and MACD, outperforming the S&P 500. Despite past challenges, recent indicators suggest a possible upward momentum in its performance.

View All News